FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897665087> ?p ?o ?g. }

• W2897665087 endingPage "S66" @default.
• W2897665087 startingPage "S66" @default.
• W2897665087 abstract "Hereditary alterations in Ataxia-Telangiectasia-Mutated (ATM) gene, a key signaling protein in the double-stranded break DNA repair process, is associated with an elevated risk of breast cancer. Here, we sought to define whether pathogenic ATM mutations present in breast cancer are associated with response to radiotherapy and exceptional responses to low dose treatment. We screened our institutional database of 21675 patients who have undergone targeted sequencing with a 468-gene panel, and identified 3773 patients with breast cancer, of whom 78 harbored ATM mutations. Among the 78 patients, 58 were treated with RT to a total of 105 different sites and were included in this analysis. Nineteen patients (33%, treated to 31 sites) had a pathogenic ATM mutation (a truncating/frameshift mutation), whereas 39 patients (67%, treated to 74 sites) had a missense ATM mutation of unknown significance. Local control (LC) after RT and toxicity were compared in patients with pathogenic ATM mutations versus those with missense mutations. Median age at time of RT was 52.2 years (range, 32.1-83.6), and median follow up among the entire cohort was 3.2 years. Three-year LC at any irradiated site was 83.3% among patients with pathogenic mutations versus 68.2% in patients with missense mutations (p=0.02). Among the 61 sites treated palliatively (median dose 30 Gy), crude rates of LC were 93.4% in patients with pathogenic ATM mutations versus 68.9% in patients with missense ATM mutations. Actuarial rates of LC at 3 years were 75% versus 42.0%, respectively (p=0.02). Among the 44 patients treated to the breast or chest wall for localized disease, crude rates of LC were 93.3% versus 79.3%, although actuarial analysis did not demonstrate a statistically significant difference. Patients with pathogenic mutations treated palliatively were more likely to experience lasting symptomatic relief from RT than patients with missense mutations (p=0.009). There were no differences in grade ≥2 acute or late toxicities among the two groups. Exceptional radiation responses were seen in individual patients with pathogenic mutations; one woman with a nonsense truncating mutation and leptomeningeal disease is now without evidence of disease in the central nervous system >10 years after whole brain RT. Patients with pathogenic ATM mutations exhibited higher LC rates than patients with missense ATM mutations of unknown significance. There does not appear to be an increase in significant acute or late toxicity after RT for patients with clinically significant somatic ATM mutations. Our findings suggest that ATM may constitute a novel mutation-based marker of radio-sensitivity in breast cancer and may facilitate personalized treatment in the future." @default.
• W2897665087 created "2018-10-26" @default.
• W2897665087 creator A5022849992 @default.
• W2897665087 creator A5034069802 @default.
• W2897665087 creator A5040506127 @default.
• W2897665087 creator A5046458547 @default.
• W2897665087 creator A5052753028 @default.
• W2897665087 creator A5058671192 @default.
• W2897665087 creator A5069071892 @default.
• W2897665087 creator A5076824413 @default.
• W2897665087 creator A5077235697 @default.
• W2897665087 creator A5084424032 @default.
• W2897665087 creator A5084723757 @default.
• W2897665087 creator A5087789652 @default.
• W2897665087 date "2018-11-01" @default.
• W2897665087 modified "2023-09-26" @default.
• W2897665087 title "Pathogenic Mutations in ATM Enhance Radio-Sensitivity and Local Control in Patients with Primary and Metastatic Breast Cancer" @default.
• W2897665087 doi "https://doi.org/10.1016/j.ijrobp.2018.06.183" @default.
• W2897665087 hasPublicationYear "2018" @default.
• W2897665087 type Work @default.
• W2897665087 sameAs 2897665087 @default.
• W2897665087 citedByCount "1" @default.
• W2897665087 countsByYear W28976650872019 @default.
• W2897665087 crossrefType "journal-article" @default.
• W2897665087 hasAuthorship W2897665087A5022849992 @default.
• W2897665087 hasAuthorship W2897665087A5034069802 @default.
• W2897665087 hasAuthorship W2897665087A5040506127 @default.
• W2897665087 hasAuthorship W2897665087A5046458547 @default.
• W2897665087 hasAuthorship W2897665087A5052753028 @default.
• W2897665087 hasAuthorship W2897665087A5058671192 @default.
• W2897665087 hasAuthorship W2897665087A5069071892 @default.
• W2897665087 hasAuthorship W2897665087A5076824413 @default.
• W2897665087 hasAuthorship W2897665087A5077235697 @default.
• W2897665087 hasAuthorship W2897665087A5084424032 @default.
• W2897665087 hasAuthorship W2897665087A5084723757 @default.
• W2897665087 hasAuthorship W2897665087A5087789652 @default.
• W2897665087 hasConcept C104317684 @default.
• W2897665087 hasConcept C121608353 @default.
• W2897665087 hasConcept C126322002 @default.
• W2897665087 hasConcept C143425029 @default.
• W2897665087 hasConcept C143998085 @default.
• W2897665087 hasConcept C2779486608 @default.
• W2897665087 hasConcept C29906990 @default.
• W2897665087 hasConcept C501734568 @default.
• W2897665087 hasConcept C502942594 @default.
• W2897665087 hasConcept C530470458 @default.
• W2897665087 hasConcept C54355233 @default.
• W2897665087 hasConcept C552990157 @default.
• W2897665087 hasConcept C71924100 @default.
• W2897665087 hasConcept C72563966 @default.
• W2897665087 hasConcept C75563809 @default.
• W2897665087 hasConcept C86803240 @default.
• W2897665087 hasConceptScore W2897665087C104317684 @default.
• W2897665087 hasConceptScore W2897665087C121608353 @default.
• W2897665087 hasConceptScore W2897665087C126322002 @default.
• W2897665087 hasConceptScore W2897665087C143425029 @default.
• W2897665087 hasConceptScore W2897665087C143998085 @default.
• W2897665087 hasConceptScore W2897665087C2779486608 @default.
• W2897665087 hasConceptScore W2897665087C29906990 @default.
• W2897665087 hasConceptScore W2897665087C501734568 @default.
• W2897665087 hasConceptScore W2897665087C502942594 @default.
• W2897665087 hasConceptScore W2897665087C530470458 @default.
• W2897665087 hasConceptScore W2897665087C54355233 @default.
• W2897665087 hasConceptScore W2897665087C552990157 @default.
• W2897665087 hasConceptScore W2897665087C71924100 @default.
• W2897665087 hasConceptScore W2897665087C72563966 @default.
• W2897665087 hasConceptScore W2897665087C75563809 @default.
• W2897665087 hasConceptScore W2897665087C86803240 @default.
• W2897665087 hasIssue "3" @default.
• W2897665087 hasLocation W28976650871 @default.
• W2897665087 hasOpenAccess W2897665087 @default.
• W2897665087 hasPrimaryLocation W28976650871 @default.
• W2897665087 hasRelatedWork W1985277533 @default.
• W2897665087 hasRelatedWork W1999949036 @default.
• W2897665087 hasRelatedWork W2019484209 @default.
• W2897665087 hasRelatedWork W2030215545 @default.
• W2897665087 hasRelatedWork W2091540373 @default.
• W2897665087 hasRelatedWork W2148226412 @default.
• W2897665087 hasRelatedWork W2162724184 @default.
• W2897665087 hasRelatedWork W2352620394 @default.
• W2897665087 hasRelatedWork W3045175301 @default.
• W2897665087 hasRelatedWork W3203072193 @default.
• W2897665087 hasVolume "102" @default.
• W2897665087 isParatext "false" @default.
• W2897665087 isRetracted "false" @default.
• W2897665087 magId "2897665087" @default.
• W2897665087 workType "article" @default.